FemPulse GmbH was founded in 2019 as a med-tech startup in Vienna and is the exclusive licensee of FemPulse Corp in the US, which is also a minority shareholder. FemPulse Corp holds a large number of international patents. Thanks to a bilateral cooperation agreement, FemPulse GmbH can access and develop the latest findings from the USA at any time.
FemPulse GmbH’s corporate objective is to develop an innovative device for the therapy of the “overactive female bladder”. The company will be active in the EU area and will work exclusively with the Pelvic Floor Centre at the Vienna General Hospital and the Medical University of Vienna. Once approval has been granted, which is expected in late-2021, FemPulse GmbH will market the product on its own account, initially within the European regulatory framework, and provide the necessary distribution.
The med-tech start-up is currently supported and promoted by aws Seedfinancing (Austria Wirtschaftsservice) and the VBA – Gründerservice. Further potential fields of research are currently in the evaluation phase.